Genentech CFO Lou Lavigne to retire
Thursday, 11 November, 2004
Genentech has announced that its chief financial officer, Lou Lavigne, will retire next March and will be replaced by David Ebersman, currently senior vice president of product operations.
Ebersman joined Genentech in 1994 and was named senior director of product development in 1998, vice president of product development in 1999 and senior vice president of product operations in 2001.
He became a member of Genentech's executive committee in March 2004.
Before joining Genentech, Ebersman was a research analyst covering biotechnology at Oppenheimer & Company, which is now CIBC World Markets. Ebersman will be replaced by Pat Yang, currently vice president of South San Francisco Manufacturing and Engineering.
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
The microbiome helps to fight melanoma
Molecules produced by gut bacteria upon digestion of dietary fibre can improve the function of...
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
